What Changed at Owkin

Every material change AI Health Index has tracked at Owkin: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact

Type

1 entry

Showing changes for Owkin only.Show the full log

August 2026

O

Owkin

Aug 18, 2026

HighVerified

Regulatory / FDA

Owkin received European regulatory approval for two first-in-class AI diagnostic solutions designed for breast cancer and colorectal cancer. The tools leverage multimodal patient data to assist in biomarker screening and outcome prediction.

Our read

European healthcare providers and laboratories can now clinically deploy these validated AI diagnostic tools. This provides pathologists and oncologists with approved decision support for breast and colorectal cancer diagnostics.

Related axis: FDA and Regulatory StatusVendor announcementView source